PLYMOUTH MEETING, PA, and MIAMI, FL — Nov 5, 2025 — The National Comprehensive Cancer Network® (NCCN®) and OpenEvidence, the leading AI-powered medical search and decision-support platform, today announced a licensing agreement to make NCCN’s trusted, evidence-based oncology guidelines accessible through OpenEvidence’s medical artificial intelligence technology.
Through this licensing agreement, OpenEvidence will integrate content from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and related content from JNCCN—Journal of the National Comprehensive Cancer Network into its clinician-facing AI platform. “NCCN works to advance quality, effective, equitable and accessible cancer care and prevention so that all people can live better lives,” said Crystal S. Denlinger, MD, FACP, Chief Executive Officer of NCCN. “Health information technology organizations like OpenEvidence can play a key role in connecting providers with leading evidence- and expert consensus-based recommendations on cancer care and prevention. This collaboration will help clinicians access trusted recommendations in a way that harnesses the evolving power of artificial intelligence to support learning and care delivery in cancer, grounded in source documentation and references.”
This collaboration will enable healthcare professionals, including the hundreds of thousands of U.S. physicians now using OpenEvidence daily, to access NCCN’s evidence-based, expert consensus-driven recommendations via natural-language search. This will allow clinicians to find the best information faster, with context and clarity, while maintaining NCCN’s rigorous standards for accuracy and quality. “NCCN guidelines are the gold standard for oncology practice around the world,” said Daniel Nadler, PhD, CEO of OpenEvidence. “We are honored to work hand-in-hand with NCCN to make this information more accessible in real time, across every clinical setting, through a secure and responsible application of AI. This collaboration represents a major leap toward making expert medical knowledge universally available and actionable.”
The collaboration reflects a shared commitment to clinical excellence, transparency, and continuous quality assurance. All NCCN content surfaced on OpenEvidence strictly adheres to NCCN’s established QA review and links to the source document for additional information. This will ensure fidelity to NCCN recommendations while OpenEvidence’s secure and proprietary systems provide additional medical evidence.
Through this collaboration, NCCN and OpenEvidence aim to expand how guideline-based knowledge reaches clinicians—combining NCCN’s unparalleled expertise in cancer care with OpenEvidence’s innovative AI technology to empower clinicians, streamline decision-making, and ultimately improve outcomes for patients worldwide.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives. Visit NCCN.org for more information on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and other initiatives.
About OpenEvidence
OpenEvidence is the most popular AI for doctors in the United States. According to independent studies, more American physicians use OpenEvidence than all other AI platforms combined. OpenEvidence is trusted by millions of verified U.S. healthcare professionals making high-stakes clinical decisions at the point of care, with evidence that is sourced, cited, and grounded in peer-reviewed medical literature. Founded with the mission to organize and expand the world's collective medical knowledge, OpenEvidence is now used daily, on average, by the majority of physicians in the United States. OpenEvidence is free for all verified U.S. clinicians. Learn more at openevidence.com.